1/16
07:03 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
1/15
08:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
1/14
07:03 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
Low
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
1/5
08:33 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
1/5
07:19 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions [Yahoo! Finance]
1/5
06:57 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
1/2
07:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at Ascendiant Capital Markets.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at Ascendiant Capital Markets.
12/24
04:15 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
04:39 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
07:32 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]
12/18
07:05 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
12/16
08:05 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
High
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
12/3
08:06 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
12/3
07:00 am
nrxp
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
Medium
Report
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
12/2
07:07 pm
nrxp
NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date [Yahoo! Finance]
12/2
11:27 am
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript [Seeking Alpha]
Medium
Report
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript [Seeking Alpha]
12/2
10:40 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
12/2
08:30 am
nrxp
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
High
Report
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
12/2
07:30 am
nrxp
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
High
Report
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
12/1
08:52 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference [Yahoo! Finance]
12/1
08:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
11/23
02:11 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by analysts at
Wall Stree
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by analysts at
Wall Stree
11/17
04:33 pm
nrxp
NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... [Yahoo! Finance]
Medium
Report
NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... [Yahoo! Finance]
11/17
01:19 pm
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/17
08:43 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.